Guanidine and amidine derivatives as factor Xa inhibitors
View Patent ↗The present invention relates to compounds of the formula I, in which R 0 ; Q; X; Q′, D, R 10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
1. A compound the following formula
wherein
R 0 is phenyl, wherein the phenyl is disubstituted independently of one another by R 2 ;
R 2 is halogen, (C 1 -C 2 )-alkyloxy, wherein the alkyloxy is unsubstituted or substituted by amino, or —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or substituted by amino;
one of Q and Q′ is direct bond and the other is —O—;
R 10 is hydrogen;
X is —CH 2 —CH 2 —;
one of R 1 ′, R 1 ″, R 1 ′″, and R 1 ″″ is hydrogen, and the others are selected from hydrogen or R 1 ;
R 1 is halogen, —OH, —NH 2 , —C(O)—NR 14 R 15 , or —(C 1 -C 3 )-alkyloxy, or —(C 1 -C 3 )-alkyl, wherein the alkyl of each group is unsubstituted or mono-, di- or trisubstituted independently of one another by R 13 ;
R 14 and R 15 are, independently, hydrogen or (C 1 -C 2 )-alkyl-;
R 13 is fluorine or chlorine;
V is a residue of formula
L is direct bond;
A is hydrogen, —C(O)—OH, —C(O)—O—(C 1 -C 4 )-alkyl, —C(O)—NR 4 R 5 or —(C 1 -C 4 )-alkyl;
U is —NH 2 , methyl, —NH—C(O)—O—(C 1 -C 4 )-alkyl or —NH—C(O)—O—(CH 2 )-phenyl;
M is hydrogen; and
R 4 and R 5 are independently of one another hydrogen or methyl;
or a stereoisomeric form or a mixture of stereoisomeric forms thereof in any ratio, or a physiologically tolerable salt thereof.
2. A process for preparing the compounds according to claim 1 , comprising linking a building block of formula XI with a fragment of formula XII,
wherein
R 0 , Q, Q′ and X, are as defined in claim 1 ,
R1′, R1″, R1′″ and R1′″ or R 1 are as defined in claim 1 , and
Y is a nucleophilically substitutable leaving group or a hydroxyl group,
wherein R 0 , R 1 , and X can also be present in protected form or in the form of precursor groups, and
wherein the formula XII is
H—NR 10 -V (XII)
wherein R10 and V are as defined in claim 1 , and can also be present in protected form or in the form of precursor groups.
3. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1 , or a stereoisomeric form or a mixture of stereoisomeric forms thereof in any ratio, or a physiologically tolerable salt thereof, and a pharmaceutically acceptable cartier.
4. A method of treating thrombosis in a host in need thereof comprising administering a therapeutically effective amount of the compound according to claim 1 , or a stereoisomeric form or a mixture of stereoisomeric forms thereof in any ratio, or a physiologically tolerable salt thereof to the host.
5. The method of claim 4 , wherein the thrombosis occurs as a result of at least one of thrombolytic therapy, surgery, a myocardial infarction, angina, or stroke.